Molecular alterations in uterine serous carcinoma

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 286-289

  Hayes, Monica Prasad ^a   Ellenson, Lora Hedrick ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Claudin 3; Claudin 4; EGFR; HER 2; PIK3CA; Uterine serous carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CLAUDIN 3; CLAUDIN 4; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; ENTEROTOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MI 63; MURINE DOUBLE MINUTE 2 PROTEIN INHIBITOR; NUTLIN 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

CLINICAL TRIAL; CLOSTRIDIUM PERFRINGENS; DRUG MECHANISM; DRUG POTENTIATION; GENE MUTATION; HUMAN; MOLECULAR DYNAMICS; ONCOGENE; ONCOGENE NEU; ONCOGENE PIK3CA; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA;

ANIMALS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; UTERINE NEOPLASMS;

EID: 73949116980     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.012     Document Type: Review

References (36)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 59 (2009) 225-249
2. Kato D.T., Ferry J.A., Goodman A., Sullinger J., Scully R.E., Goff B.A., et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol. Oncol. 59 (1995) 384-389
3. Bristow R.E., Asrari F., Trimble E.L., and Montz F.J. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol. Oncol. 81 (2001) 279-286
4. Ramondetta L., Burke T.W., Levenback C., Bevers M., Bodurka-Bevers D., and Gershenson D.M. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol. Oncol. 82 (2001) 156-161
5. Hoskins P.J., Swenerton K.D., Pike J.A., Wong F., Lim P., Acquino-Parsons C., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J. Clin. Oncol. 19 (2001) 4048-4053
6. Kelly M.G., O Malley D., Hui P., McAlpine J., Dziura J., et al. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol. Oncol. 95 (2004) 469-473
7. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57 (1997) 3935-3940
8. Canner J.A., Sobo M., Ball S., Hutzen B., DeAngelis S., Willis W., et al. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br. J. Cancer 101 (2009) 774-781
9. Miyachi M., Kakazu N., Yagyu S., Katsumi Y., Tsubai-Shimizu S., Kikuchi K., et al. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin. Cancer Res. 15 (2009) 4077-4084
10. Tabe Y., Sebasigari D., Jin L., Rudelius M., Davies-Hill T., Miyake K., et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin. Cancer Res. 15 (2009) 933-942
11. Slomovitz B.M., Broaddus R.R., Burke T.W., Sneige N., Soliman P.T., Wu W., et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol. 22 (2004) 3126-3132
12. Villella J.A., Cohen S., Smith D.H., Hibshoosh H., and Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int. J. Gynecol. Cancer 16 (2006) 1897-1902
13. Grushko T.A., Filiaci V.L., Mundt A.J., Ridderstrale K., Olopade O.I., and Fleming G.F. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 108 (2008) 3-9
14. Rolitsky C.D., Theil K.S., McGaughy V.R., Copeland L.J., and Niemann T.H. HER-2/neu amplification and overexpression in endometrial carcinoma. Int. J. Gynecol. Pathol. 18 (1999) 138-143
15. Santin A.D., Bellone S., Van Stedum S., Bushen W., De Las Casas L.E., Korourian S., et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol. Oncol. 98 (2005) 24-30
16. Fleming G.F., Sill M.W., Darcy K.M., McMeekin D.S., Thigpen J.T., Adler L.M., et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 116 (2010) 15-20
17. Konecny G.E., Venkatesan N., Yang G., Dering J., Ginther C., Finn R., et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br. J. Cancer 98 (2008) 1076-1084
18. Medina P.J., and Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 30 (2008) 1426-1447
19. Konecny G.E., Santos L., Winterhoff B., Hatmal M., Keeney G.L., Mariani A., et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br. J. Cancer 100 (2009) 89-95
20. Hayes M.P., Douglas W., and Ellenson L.H. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol. Oncol. 113 (2009) 370-373
21. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
22. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13306-13311
23. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
24. Kang S., Bader A.G., and Vogt P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 802-807
25. Bader A.G., Kang S., and Vogt P.K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1475-1479
26. Samuels Y., Diaz Jr. L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 (2005) 561-573
27. Oda K., Stokoe D., Taketani Y., and McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65 (2005) 10669-10673
28. Hayes M.P., Wang H., Espinal-Witter R., Douglas W., Solomon G.J., Baker S.J., et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin. Cancer Res. 12 (2006) 5932-5935
29. Oza A.M., Elit L., Provencher D., Biagi J.J., Panasci L., Sederias J., et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J. Clin. Oncol. 26 (2008) (Meeting Abstracts 5516)
30. Buck E., Eyzaguirre A., Brown E., Petti F., McCormack S., Haley J.D., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 5 (2006) 2676-2684
31. Santin A.D., Zhan F., Bellone S., Palmieri M., Cane S., Gokden M., et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br. J. Cancer 90 (2004) 1814-1824
32. Santin A.D., Bellone S., Marizzoni M., Palmieri M., Siegel E.R., McKenney J.K., et al. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer 109 (2007) 1312-1322
33. Konecny G.E., Agarwal R., Keeney G.A., Winterhoff B., Jones M.B., Mariani A., et al. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol. Oncol. 109 (2008) 263-269
34. Agarwal R., D Souza T., and Morin P.J. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 65 (2005) 7378-7385
35. Romani C., Comper F., Bandiera E., Ravaggi A., Bignotti E., Tassi R.A., et al. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. Am. J. Obstet. Gynecol. 201 70 (2009) e1-e9
36. Aghajanian C., Sill M.W., Darcy K., Greer B., McMeekin D.S., Rose P.G., et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) Study. J. Clin. Oncol. 27 (2009) (Meeting Abstracts 5531)